Coumaran Egile Selected Research

XL765

4/2018	Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial.
9/2015	Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma.
6/2015	Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphoma.
5/2014	Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Coumaran Egile Research Topics

Disease

8	Neoplasms (Cancer) 10/2023 - 01/2007
3	Lymphoma (Lymphomas) 04/2018 - 06/2015
2	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 04/2018 - 07/2015
2	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 04/2018 - 06/2015
2	Stomach Neoplasms (Stomach Cancer) 11/2016 - 02/2015
2	Cicatrix (Scar) 01/2012 - 11/2004
1	Nausea 01/2021
1	Disease Progression 01/2021
1	Vomiting 01/2021
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 04/2018
1	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 04/2018
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 04/2018
1	Glioma (Gliomas) 09/2015
1	Neoplasm Metastasis (Metastasis) 02/2015
1	Exanthema (Rash) 02/2015
1	Diarrhea 02/2015
1	Body Weight (Weight, Body) 02/2015
1	Endometrial Neoplasms (Endometrial Cancer) 02/2015
1	Squamous Cell Carcinoma of Head and Neck 01/2014
1	Adenomatous Polyposis Coli (Familial Adenomatous Polyposis) 01/2007
1	Poisoning 10/2004

Drug/Important Bio-Agent (IBA)

4	XL765IBA 04/2018 - 05/2014
4	Phosphotransferases (Kinase)IBA 11/2016 - 01/2014
3	Phosphatidylinositols (Phosphatidylinositol)IBA 09/2015 - 05/2014
3	XL147IBA 07/2015 - 01/2014
3	Proteins (Proteins, Gene)FDA Link 01/2007 - 10/2004
2	TOR Serine-Threonine KinasesIBA 09/2015 - 06/2015
2	Actin-Related Protein 2-3 Complex (Arp2 3 Complex)IBA 01/2012 - 11/2004
2	Carrier Proteins (Binding Protein)IBA 01/2007 - 11/2004
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 10/2023
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 10/2023
1	Tyrosine Kinase InhibitorsIBA 01/2021
1	Gefitinib (Iressa)FDA Link 01/2021
1	1- (1- (imidazo(1,2- a)pyridin- 6- yl)ethyl)- 6- (1- methyl- 1H- pyrazol- 4- yl)- 1H- (1,2,3)triazolo(4,5- b)pyrazineIBA 01/2021
1	ErbB Receptors (EGF Receptor)IBA 01/2021
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2021
1	Temozolomide (Temodar)FDA LinkGeneric 09/2015
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 06/2015
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 02/2015
1	Alanine Transaminase (SGPT)IBA 02/2015
1	PTEN Phosphohydrolase (PTEN Phosphatase)IBA 02/2015
1	Circulating Tumor DNAIBA 02/2015
1	SAR125844IBA 02/2015
1	Mechanistic Target of Rapamycin Complex 1IBA 05/2014
1	Mechanistic Target of Rapamycin Complex 2IBA 05/2014
1	CortactinIBA 01/2012
1	beta CateninIBA 01/2007
1	Monomeric GTP-Binding ProteinsIBA 01/2007
1	Calmodulin (Calcium-Dependent Activator Protein)IBA 01/2007
1	Wiskott-Aldrich Syndrome ProteinIBA 11/2004
1	Actin Depolymerizing Factors (Cofilins)IBA 11/2004
1	Cyclic AMP Receptors (Cyclic AMP Receptor)IBA 11/2004
1	Plant ProteinsIBA 11/2004
1	Wiskott-Aldrich Syndrome Protein FamilyIBA 11/2004
1	ForminsIBA 10/2004

Therapy/Procedure

1	Radiotherapy 09/2015
1	Drug Therapy (Chemotherapy) 02/2015
1	Therapeutics 02/2015